19 – 23 October 2026 | Gold Coast
Capital Sprint, is a new fast-paced company presentation format within the Investment & Global Growth stream at the AusBiotech International Conference. Capital Sprint has been designed to give investors a concise view of selected life sciences companies at key capital or commercial inflection points. Applications were received through the AusBiotech Investor Readiness Platform.
Capital Sprint: Public Markets showcases listed life sciences companies with established market relevance, substantive progress or validation, and significant value-inflection points ahead.
In a series of rapid three-minute, no-slide pitches, selected companies will distil their current market position, key evidence and progress, upcoming catalysts, and pathway to shareholder value creation.
Designed for public-market investors and other capital-market participants, Capital Sprint: Public Markets provides a concise view of listed biotechnology, medtech and health innovation companies with clear upcoming catalysts and a forward-looking capital-market story.
The format is intentionally direct: no slides, no extended corporate presentations, just a concise articulation of what investors should understand about the company now.
Event: Wednesday October 21st, 4.30pm
The five participating companies are:
Avecho Biotechnology develops pharmaceutical products using its proprietary TPM drug delivery technology. Its lead program is an oral cannabidiol formulation being investigated in a Phase III clinical trial for insomnia.
BlinkLab Limited is developing AI-powered, smartphone-based technology to support clinicians in assessing autism. Its approach measures reflex responses to provide objective information that can complement clinical observation.
Starpharma develops pharmaceutical applications of dendrimers, precisely structured nanoscale molecules. Its DEP drug delivery platform is designed to improve how medicines are delivered and perform, with a particular focus on cancer treatments.
Alterity Therapeutics is developing treatments intended to modify the course of neurodegenerative diseases. Its lead candidate, ATH434, is being developed for multiple system atrophy, a rare and progressive neurological condition.
Optiscan develops microscopic imaging technology that enables clinicians and researchers to view tissue at the cellular level in real time. Its technology supports applications in digital pathology and precision surgery, helping inform decisions about tissue during procedures.
Capital Sprint: Venture showcases private life sciences companies with a well-defined investment proposition, substantive evidence or external validation, and a clear next value-creation milestone. In a series of rapid three-minute, no-slide pitches, selected companies will outline where they are now, the evidence and progress underpinning their opportunity, the next value-inflection point, and the capital required to get there.
Designed for investors and other capital-market participants, Capital Sprint: Venture provides a fast-paced view of biotechnology, medtech and health innovation companies with a credible pathway to their next stage of growth.
The format is intentionally direct: no slides, no long presentations, just a clear articulation of the company, the opportunity, the next milestone and how achieving it creates value.
Event: Thursday October 22nd, 3.50pm.
Capital Sprint: Venture is sponsored by Google Cloud
The six participating companies are:
Anaxis Pharma is developing small-molecule medicines targeting necroptosis, a form of cell death that drives inflammation. Its research aims to create new treatment options for people with chronic inflammatory diseases.
Delica Bio uses cell-free synthesis and biocatalysis to produce naturally occurring compounds with therapeutic potential. The Australian company focuses on compounds that are difficult to manufacture, aiming to make them more accessible for pharmaceutical development.
FivepHusion is developing cancer treatments designed to improve patient outcomes and quality of life. Its lead program, Deflexifol, is a novel formulation intended to address limitations in existing chemotherapy treatment.
HaemaLogiX is developing targeted immunotherapies for blood cancers and B-cell disorders, with a particular focus on multiple myeloma. Its pipeline includes antibody and CAR-T cell therapies designed to recognise specific targets on cancerous cells while sparing healthy plasma cells.
Novoroo Bioscience is developing biological therapies aimed at restoring the capacity of the brain and spinal cord to repair damage. Its research spans spinal cord injury, multiple sclerosis and conditions involving abnormal tau protein, including Alzheimer’s disease.
TargTex is developing treatments delivered directly to hard-to-treat tumours, with a lead program targeting glioblastoma, an aggressive brain cancer. Its hydrogel delivery approach is designed to place therapy at the tumour site during surgery to target remaining cancer cells.
Presenting companies for Capital Sprints were selected from companies who engaged through AusBiotech’s Investor Readiness Platform (IRP) and related investor-readiness processes.
The IRP is open year-round and helps AusBiotech identify companies for investment-focused opportunities across programs and events.
Companies interested in being considered for future opportunities should review the application process.
Position your organisation at the forefront of Australia’s life sciences sector with a BioInnovation Spotlight session.
Located in the heart of the exhibition hall, the BioInnovation Spotlight stage provides a high-impact platform for organisations to showcase breakthrough technologies, products, services, and innovative solutions through a compelling 10-minute presentation to an engaged audience of industry leaders, investors, researchers and decision-makers.
Held during the conference catering breaks, these sessions are designed to maximise visibility, drive meaningful conversations and generate new business opportunities when delegate traffic is at its highest.
Held from 2.15pm on Wednesday October 21st The Early-Stage Innovation Forum, sponsored by West Pharmaceuticals, is designed to help Australia’s most promising life sciences innovations move from discovery towards commercialisation.
Unlike traditional investor pitch events, this forum provides a supportive environment where researchers and founders can showcase their innovation, receive expert feedback and build valuable industry connections before embarking on larger fundraising activities.
Participants may be working on a novel therapeutic, medical device, diagnostic, digital health platform or enabling technology, and will be selected through the Investor Readiness Platform (IRP)
